Introduction
Chronic graft-versus-host disease (cGVHD) is a common late complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) characteristically showing clinical manifestations that resemble autoimmune disorders. cGVHD may affect up to 60% of patients who undergo HLA-identical allo-HSCT and survive beyond 100 days. This disease affects a variety of organs, including the oral mucosa, intestinal tract, liver, eyes, lungs, bone marrow, muscles and frequently the skin [1] [2] . In many patients GVHD develops despite prophylactic treatment, which often includes low doses of methotrexate combined with cyclosporine; both GVHD and this combination treatment often decreases the quality of life and increases morbidity and mortality [3] [4] .
The most common first-line treatment for cGVHD is steroids in combination with cyclosporine or another calcineurin inhibitor. For patients with steroid-resistant cGVHD, a second-line treatment is less well defined due to the lack of clinical studies 5 .
There are numerous single drugs or combination therapies that can be used to treat steroid-resistant cGVHD, including calcineurin inhibitors, pulses of high doses of methylprednisolone, photopheresis, mycophenolate mofetil, immunomodulating agents like thalidomide, azathioprine, rituximab, hydroxychloroquine, imatinib, alemtuzumab, thoracoabdominal irradiation, etc. [5] [6] . However, most of these treatments, such as rituximab, are classified as C-2 level (recommended second-line treatment), and compounds like alemtuzumab are classified as C-4 level (experimental, used only in clinical trials or individual cases) 5 . Rituximab is a monoclonal anti-CD20 antibody used for treating non-Hodgkin lymphoma and several autoimmune diseases. Rituximab causes a rapid depletion of pre-B and mature B cells, which remain at low levels for 3 to 6 months 7 . Some studies have demonstrated that rituximab is effective for cGVHD treatment because B cells play a role in its pathogenesis, especially in patients with immune cytopenia and skin involvement 8 . Alemtuzumab, on the other hand, is an anti-CD52 IgG monoclonal antibody that demonstrates activity against B cells, T cells and Natural Killer cells [9] [10] . Currently, alemtuzumab is mainly used to treat B cell chronic lymphocytic leukemia; however, this drug has also been used in conditioning regimens for allo-HSCT, and several reports have shown that treatment with this monoclonal antibody reduced the incidence of both acute and chronic GVHD [11] [12] . There is limited information regarding the use of alemtuzumab for cGVHD treatment consisting of small series and a few case reports [13] [14] .
A simultaneous depletion of both B cells and T cells may be an optimal treatment strategy for cGVHD, gaining a tighter control of the strong immune response driving cGVHD pathophysiology. Acting on this rationale, we prospectively analyzed the effect of low doses of subcutaneous alemtuzumab in combination with low doses of rituximab on 15 steroid-refractory cGVHD patients. Our goal was to determine the effectiveness and safety profile of this biological combination therapy.
Design and methods
The protocol was approved by the local Ethics Committee, and all of the patients signed Table 1 .
GVHD diagnosis and staging
cGVHD diagnosis was based on clinical manifestations and laboratory test results according to the NIH consensus criteria on the diagnosis and staging of cGVHD 2 ; the results were confirmed with a biopsy when it was necessary to rule out others diagnosis.
Chronic GVHD was scored in 4 levels (0-3) according to the consensus scoring system 2 . Before cGVHD diagnosis was established drug reaction, infection and malignancy were excluded as the cause of the clinical manifestations.
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Study drug administration
All of the 15 patients were receiving cyclosporine A (CSA) and prednisone at the time of entering the study. When the patients initiated alemtuzumab-rituximab treatment, the prednisone dose was gradually decreased over the next 15 days and eventually stopped.
The cyclosporine dose was reduced to 50% when cGVHD complete remission was achieved, independently of the CSA serum levels. Alemtuzumab was administered subcutaneously on cycle days 1 to 3 at a dose of 10 mg/day. One 30 mg alemtuzumab vial was used for each patient, and prophylactic medication was not necessary.
Rituximab was given intravenously on days +4, +11, +18 and +25 of one cycle at a total dose of 100 mg each day. Prior to rituximab administration, paracetamol and chlorpheniramine were administered as prophylactic premedication. The planned 
Response definition
There is no simplified method for quantification of a therapeutic response to cGVHD.
The therapeutic response was based on clinician's assessment, patient symptom intensity self-report, laboratory results and functional status. The therapeutic response was measured on days +30, +90 and +365 of the protocol. Data obtained at each evaluation were compared to the basal data. A complete response was defined as resolution of all manifestations related to cGVHD in a specific organ. Partial response was defined as an improvement in at least 50% of the cGVHD manifestations.
Progression was defined as an increase in symptoms, signs or laboratory test abnormalities.
Results
Fifteen consecutive patients with steroid refractory cGVHD were included in this study.
The median age of the group was 41 years (range 20-57 years). All 10 men and 5
women had GVHD prophylaxis failure and did not respond to a combination treatment with steroids and CSA. Four patients (27%) had acute GVHD and achieved remission with CSA and prednisone; however, these patients eventually developed cGVHD after several months and then were included in the study. Four patients had cGVHD for more than 1 year, and 2 of these patients had avascular necrosis of the femoral head that was related to the chronic use of steroids. Most of the patients had 2 or more organs involved including the oral mucosa (86.7%), eyes (66.7%), liver (60%), skin (53%), lungs (13.3%) and intestinal tract (6.7%). Alemtuzumab-rituximab therapy was initiated at a median of 31 months (range 2-128 months) after cGVHD diagnosis. Previous cGVHD treatments included CSA, steroids and phototherapy (PUVA). Three patients received alemtuzumab or rituximab as a single drug for more than 60 days prior to inclusion on the protocol; none of the patients responded to single drug treatment ( Table   1 ). All of the patients included in this study completed the therapeutic schedule with a median follow-up of 232 days (range 72-618).
The overall response was 100% at the +30-day evaluation; 10 patients (67%) had partial remission, and 5 patients (33%) had complete remission. For the patients with complete remission, the CSA dose was gradually decreased and ultimately stopped. For the patients with partial remission the CSA dose was reduced to 50% of its initial value.
Patient number 4 had diarrhea grade 1 that disappeared at day 11 th of the protocol (table   2) . At the +90-day evaluation, 7 (50%) patients had a partial response, 4 (28%) had a complete response, 3 (21%) had cGVHD relapsed and 1 patient had not yet reached 90 days post-treatment. One patient (patient number 6) who had attained cGVHD partial remission had a leukemia relapse (acute promyelocytic leukemia) and received a second allo-HSCT; this patient achieved complete remission without GVHD. Of the patients with relapsed cGVHD who restarted steroid treatment, one received a second cycle of alemtuzumab-rituximab treatment and achieved a second partial remission (number 14), and 2 patients (numbers 3 and 13) received four monthly doses of 100 mg rituximab and achieved complete remission (Table 2 ). Currently, only 5 patients are available to evaluate the +365-day follow-up; 2 of them (40%) have a partial response, 2 have a complete response and 1 shows progression of cGVHD (Table 2 ).
Acute side effects of alemtuzumab administration occurred in only one patient who had fever and chills after the third dose. The fever and chills appeared 30 minutes after alemtuzumab administration and disappeared after acetaminophen was administered.
Acute side effects of rituximab occurred in 7 patients during intravenous infusion of the drug, including chills in 4, rash in 2 and a fever in 1 patient. A majority of the side effects occurred during the first rituximab infusion and disappeared after the infusion velocity was decreased and 100 mg of hydrocortisone was co-administrated. The late side effects of the therapy were mainly infectious, including laryngitis, sinusitis, pneumonia, urinary tract infection and oral herpes simplex virus infection in 1 patient each, bronchitis in 2 and reactivation of cytomegalovirus in 3 patients; acute promyelocytic leukemia relapse was observed in one patient once he achieved complete cGVHD remission. The patient number 10 ( in most of the patients, but had no effect on severe cutaneous and ocular manifestations 17 . Most studies have shown an overall response between 43% and 83% [17] [18] [19] [20] [21] [22] . A metaanalysis by Kharfan-Dabaja et al. reported an overall rituximab response of 66%, with improvements mainly in the skin (60%), oral mucosa (36%), hepatic (29%), gastrointestinal (31%) and pulmonary lesions (30%) 23 .
The optimal rituximab dose for immune-mediated hematological disorders has not been established. In most studies, the doses are similar to the dosing for non-Hodgkin's lymphoma 24 . However, because the number of lymphocytes in cGVHD is expected to be lower, lower doses of the monoclonal antibodies may be required. Zaja et al.
demonstrated that low dose rituximab, weekly 100 mg, can produce significant and durable responses which are associated with B cell depletion in patients with autoimmune cytopenias [25] [26] . Thus, we assessed the therapeutic benefit of a low dose combination of alemtuzumab and rituximab that was subcutaneously administered.
In our study, we used an alemtuzumab-rituximab therapeutic combination to reduce both B and T lymphocyte activity and reduce the clinical manifestations of cGVHD.
This combination has been used previously to treat chronic lymphocytic leukemia 27 ; moreover, our group has successfully used this combination to treat autoimmune cytopenias, finding that the patients responded well and there were no toxicities noted 28 .
In the present study the maximal response occurred early after patients finished their treatment with the drug combination producing an overall response rate of 100% at the +30-day evaluation; 10 patients achieved a partial remission (67%), and 5 complete remission (33%). The clinical manifestations of cGVHD improved faster than expected, which allowed us to stop prednisone treatment without complications in all of the patients. The number of lymphocytes noticeably decreased at this point and slowly increased over time. At the +90-day evaluation, we observed some changes in the response index. Three patients with previous partial remission showed cGVHD progression, despite a low lymphocyte count (< 500 K/uL); however, these 3 patients responded well to a second cycle of alemtuzumab-rituximab or to monthly rituximab treatment, as previously described. It is important to note that cGVHD progression in these 3 patients may be related to a decrease in alemtuzumab-rituximab therapeutic activity and changes in the dose of immunosuppressive therapy. Better strategies should be designed based in this finding to prevent the GVHD progression.
Currently, 5 patients have survived 365 days for follow-up evaluation; one showed cGVHD progression with skin involvement indicated by pigmentary changes and sclerotic lesions. The patient received a second alemtuzumab-rituximab cycle and eventually achieved partial remission.
Acute adverse events during alemtuzumab-rituximab delivery were mild and quickly solved in all of the cases. Several studies have indicated that alemtuzumab and rituximab treatment predisposes the patient to opportunistic infections 15, [29] [30] [31] [32] [33] .
Alemtuzumab has been associated with infections such as CMV, adenovirus and toxoplasmosis 15 . Park et al. reported a CMV infection rate of 41.6%, and a 90% CMV infection recurrence rate in 12 patients who received an alemtuzumab-based conditioning regimen for all-HSCT 34 . Treatment with rituximab has also been associated with viral and opportunistic infections; Kimby reported a 30% incidence of infection in patients who received rituximab 7 . In our study, the incidence of infection was 67%; however, most of the infections were grade 2 and resolved in an outpatient setting. One patient died from pneumonia caused by a Rhodococcus equi infection; this is an anaerobic, gram-positive coryneform bacterium that is an opportunistic pathogen which mainly infects HIV-positive patients 35 . There are a number of additional factors in our patients that may predispose them to diverse infections. The ingestion of additional medications, the effect of cGVHD, as well as other medical problems may influence the patient's immune response. All of the patients included in this study were previously taking steroids and CSA for a long period; this chronic immunosuppression may have made the patients more susceptible to infection.
In conclusion, low dose alemtuzumab-rituximab combination therapy appears to be an efficacious and safe treatment for steroid-refractory cGVHD. Longer follow-up is necessary in this study in order to determine the durability of response and survival.
Moreover, additional low monthly doses of rituximab may extend this response. Future studies assessing the benefits of low or conventional doses of rituximab for maintenance are needed to assess the long-term efficacy.
Authorship and Disclosures
The 
